Reducing Treatment Burden in AMD.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 32200797.
- Also identified by DOI 10.1016/j.cell.2020.02.028 and PMC identifier 7460805.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
VEGF-A antagonists have revolutionized wet AMD treatment. Several challenges remain including high treatment burden requiring repeated intraocular injections for persistent disease. Brolucizumab directly inhibits VEGF-A function, providing visual outcomes comparable to aflibercept (an FDA-approved VEGF-A antagonist). Anatomic retinal outcomes including retinal fluid, a marker of disease activity, favored brolucizumab. To view this Bench to Bedisde, open or download the PDF.
Medical subject headings
- Antibodies, Monoclonal, Humanized
- Macular Degeneration